Chondrosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Chondrosarcoma is a rare malignant tumor that forms a cartilaginous matrix. Chondrosarcomas arising de novo are termed primary chondrosarcomas, while those developing in pre-existing benign cartilaginous tumors such as osteochondroma or enchondroma are referred to as secondary chondrosarcomas. CHS constitutes various groups of malignant bone tumors and encompasses multiple histological subtypes. Overall, conventional CHS is the most common subtype. It accounts for 85% of CHS, followed by dedifferentiated (10%), mesenchymal and clear cell CHS, these two representing less than 2% of all CHS cases. Conventional CHS can develop de novo or in a pre-existing enchondroma and osteochondroma. CHS is classified into three grades based on cellular atypia, mitotic figures, and cellularity. CHS grades 1 and 2 are represented by 85% of all CHSs, 15% of cases are grade 3, and the dedifferentiated CHS. According to the latest WHO recommendations, CHS should be classified into central or secondary peripheral atypical cartilaginous tumor/CHS (grade 1), central or secondary peripheral CHS grade 2 and 3.
·
The estimated overall Chondrosarcoma incidence
is 1 per 200,000/year and accounts for 20–30% of primary malignant bone tumors.
The majority of cases occur after age 50, with a slight male predominance. The
incidence of pediatric chondrosarcoma is less than 10% of all chondrosarcoma
cases, with higher survival rates than adults.
Thelansis’s
“Chondrosarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2023 To 2033" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Chondrosarcoma treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights of Chondrosarcoma across
8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Chondrosarcoma
Market Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Chondrosarcoma,
Chondrosarcoma market outlook, Chondrosarcoma competitive landscape, Chondrosarcoma market forecast, Thelansis, Primary market research, KOL
insights, Competitive Intelligence (CI)
Comments
Post a Comment